Cargando…

1462. The protective effect of pneumococcal vaccination on cardiovascular disease in adults: A systematic review and meta-analysis

BACKGROUND: Epidemiological studies suggest a link between pneumococcal infection and an adverse cardiovascular outcome such as myocardial infarction. Therefore, studies have evaluated the protective effect of the 23-valent polysaccharide pneumococcal vaccination (PPV23), but results have varied. We...

Descripción completa

Detalles Bibliográficos
Autores principales: Marra, Fawziah, Zhang, Angel, Gillman, Emma, Bessai, Katherine, Parhar, Kamalpreet, Vadlamudi, Nirma Khatri
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776373/
http://dx.doi.org/10.1093/ofid/ofaa439.1643
_version_ 1783630667606654976
author Marra, Fawziah
Zhang, Angel
Gillman, Emma
Bessai, Katherine
Parhar, Kamalpreet
Vadlamudi, Nirma Khatri
author_facet Marra, Fawziah
Zhang, Angel
Gillman, Emma
Bessai, Katherine
Parhar, Kamalpreet
Vadlamudi, Nirma Khatri
author_sort Marra, Fawziah
collection PubMed
description BACKGROUND: Epidemiological studies suggest a link between pneumococcal infection and an adverse cardiovascular outcome such as myocardial infarction. Therefore, studies have evaluated the protective effect of the 23-valent polysaccharide pneumococcal vaccination (PPV23), but results have varied. We conducted a meta-analysis to summarize the available evidence on the impact of PPV23 on cardiovascular disease METHODS: A literature search from January 1946 to September 2019 was conducted in Embase, Medline and Cochrane. All studies evaluating PPV23 compared to a control (placebo, no vaccine or another vaccine) for any cardiovascular events including myocardial infarction (MI), heart failure, cerebrovascular events were included. Risk ratios (RRs) were pooled using random effects models. RESULTS: Eighteen studies were included, with a total of 716,108 participants. Vaccination with PPV23 was associated with decreased risk of any cardiovascular event (RR: 0.91;95% CI: 0.84-0.99), and MI (RR of 0.88; 95% CI:0.79-0.98) in all age groups, with a significant effect in those 65 years and older, but not in the younger age group. Similarly, PPV23 vaccine was associated with significant risk reduction in all-cause mortality in all ages (RR: 0.78; 95%CI: 0.68-0.88), specifically in those aged 65 years and older (RR: 0.71; 95%CI: 0.60-0.84). A significant risk reduction in cerebrovascular disease was not observed following pneumococcal vaccination. CONCLUSION: Polysaccharide pneumococcal vaccination decreases the risk of a cardiovascular event, specifically acute MI in the vaccinated population, particularly those 65 years of age and older. It would be highly beneficial to vaccinate the population who is at greater risk for cardiovascular diseases. DISCLOSURES: Fawziah Marra, BSc (Pharm), PharmD, Pfizer Inc (Research Grant or Support) Nirma Khatri Vadlamudi, BA, BS, MPH, Pfizer Inc (Research Grant or Support)
format Online
Article
Text
id pubmed-7776373
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-77763732021-01-07 1462. The protective effect of pneumococcal vaccination on cardiovascular disease in adults: A systematic review and meta-analysis Marra, Fawziah Zhang, Angel Gillman, Emma Bessai, Katherine Parhar, Kamalpreet Vadlamudi, Nirma Khatri Open Forum Infect Dis Poster Abstracts BACKGROUND: Epidemiological studies suggest a link between pneumococcal infection and an adverse cardiovascular outcome such as myocardial infarction. Therefore, studies have evaluated the protective effect of the 23-valent polysaccharide pneumococcal vaccination (PPV23), but results have varied. We conducted a meta-analysis to summarize the available evidence on the impact of PPV23 on cardiovascular disease METHODS: A literature search from January 1946 to September 2019 was conducted in Embase, Medline and Cochrane. All studies evaluating PPV23 compared to a control (placebo, no vaccine or another vaccine) for any cardiovascular events including myocardial infarction (MI), heart failure, cerebrovascular events were included. Risk ratios (RRs) were pooled using random effects models. RESULTS: Eighteen studies were included, with a total of 716,108 participants. Vaccination with PPV23 was associated with decreased risk of any cardiovascular event (RR: 0.91;95% CI: 0.84-0.99), and MI (RR of 0.88; 95% CI:0.79-0.98) in all age groups, with a significant effect in those 65 years and older, but not in the younger age group. Similarly, PPV23 vaccine was associated with significant risk reduction in all-cause mortality in all ages (RR: 0.78; 95%CI: 0.68-0.88), specifically in those aged 65 years and older (RR: 0.71; 95%CI: 0.60-0.84). A significant risk reduction in cerebrovascular disease was not observed following pneumococcal vaccination. CONCLUSION: Polysaccharide pneumococcal vaccination decreases the risk of a cardiovascular event, specifically acute MI in the vaccinated population, particularly those 65 years of age and older. It would be highly beneficial to vaccinate the population who is at greater risk for cardiovascular diseases. DISCLOSURES: Fawziah Marra, BSc (Pharm), PharmD, Pfizer Inc (Research Grant or Support) Nirma Khatri Vadlamudi, BA, BS, MPH, Pfizer Inc (Research Grant or Support) Oxford University Press 2020-12-31 /pmc/articles/PMC7776373/ http://dx.doi.org/10.1093/ofid/ofaa439.1643 Text en © The Author 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Poster Abstracts
Marra, Fawziah
Zhang, Angel
Gillman, Emma
Bessai, Katherine
Parhar, Kamalpreet
Vadlamudi, Nirma Khatri
1462. The protective effect of pneumococcal vaccination on cardiovascular disease in adults: A systematic review and meta-analysis
title 1462. The protective effect of pneumococcal vaccination on cardiovascular disease in adults: A systematic review and meta-analysis
title_full 1462. The protective effect of pneumococcal vaccination on cardiovascular disease in adults: A systematic review and meta-analysis
title_fullStr 1462. The protective effect of pneumococcal vaccination on cardiovascular disease in adults: A systematic review and meta-analysis
title_full_unstemmed 1462. The protective effect of pneumococcal vaccination on cardiovascular disease in adults: A systematic review and meta-analysis
title_short 1462. The protective effect of pneumococcal vaccination on cardiovascular disease in adults: A systematic review and meta-analysis
title_sort 1462. the protective effect of pneumococcal vaccination on cardiovascular disease in adults: a systematic review and meta-analysis
topic Poster Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776373/
http://dx.doi.org/10.1093/ofid/ofaa439.1643
work_keys_str_mv AT marrafawziah 1462theprotectiveeffectofpneumococcalvaccinationoncardiovasculardiseaseinadultsasystematicreviewandmetaanalysis
AT zhangangel 1462theprotectiveeffectofpneumococcalvaccinationoncardiovasculardiseaseinadultsasystematicreviewandmetaanalysis
AT gillmanemma 1462theprotectiveeffectofpneumococcalvaccinationoncardiovasculardiseaseinadultsasystematicreviewandmetaanalysis
AT bessaikatherine 1462theprotectiveeffectofpneumococcalvaccinationoncardiovasculardiseaseinadultsasystematicreviewandmetaanalysis
AT parharkamalpreet 1462theprotectiveeffectofpneumococcalvaccinationoncardiovasculardiseaseinadultsasystematicreviewandmetaanalysis
AT vadlamudinirmakhatri 1462theprotectiveeffectofpneumococcalvaccinationoncardiovasculardiseaseinadultsasystematicreviewandmetaanalysis